Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
SFOSF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.75 | -0.46 | -0.68 | 0.51 |
| FCF Yield | 0.19% | -4.61% | -2.90% | -1.44% |
| EV / EBITDA | 6.18 | 10.48 | 9.11 | 9.67 |
| Quality | ||||
| ROIC | 3.62% | 3.11% | 8.34% | 6.62% |
| Gross Margin | 47.97% | 47.84% | 47.28% | 48.14% |
| Cash Conversion Ratio | 1.27 | 1.43 | 1.07 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.24% | 2.01% | 13.19% | 10.92% |
| Free Cash Flow Growth | 103.47% | -15.03% | -63.24% | 44.88% |
| Safety | ||||
| Net Debt / EBITDA | 2.11 | 2.98 | 1.78 | 1.58 |
| Interest Coverage | 2.96 | 2.50 | 8.61 | 7.68 |
| Efficiency | ||||
| Inventory Turnover | 2.94 | 2.86 | 3.37 | 3.70 |
| Cash Conversion Cycle | 105.36 | 108.79 | 77.29 | 67.95 |